公开(公告)号：US11618746B2

公开(公告)日：2023-04-04

申请号：US16717099

申请日：2019-12-17

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Jingrong Cao ,  Jon H. Come ,  Leslie A. Dakin ,  Francois Denis ,  Warren A. Dorsch ,  Anne Fortier ,  Martine Hamel ,  Elaine B. Krueger ,  Brian Ledford ,  Suganthini S. Nanthakumar ,  Olivier Nicolas ,  Camil Sayegh ,  Timothy J. Senter ,  Tiansheng Wang ,  Michael Brodney ,  Kan-Nian Hu ,  Peter Rose ,  Kevin Gagnon ,  Yi Shi ,  Muna Shrestha ,  Ales Medek ,  Faith Witkos

IPC: C07D403/12 ,  C07D405/14

Abstract: The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).

公开(公告)号：US20230014907A1

公开(公告)日：2023-01-19

申请号：US17345256

申请日：2021-06-11

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Leslie A. Dakin ,  Timothy J. Senter ,  Jingrong Cao ,  Jon H. Come ,  Francois Denis ,  Warren A. Dorsch ,  Anne Fortier ,  Martine Hamel ,  Elaine B. Krueger ,  Brian Ledford ,  Francois Maltais ,  Suganthini S. Nanthakumar ,  Olivier Nicolas ,  Camil E. Sayegh ,  Tiansheng Wang

IPC: C07D209/18 ,  C07D403/12 ,  C07D405/12 ,  C07D401/12 ,  C07D403/06 ,  C07D413/12 ,  C07D401/06 ,  C07D417/12 ,  C07D409/12 ,  C07D209/40 ,  C07D209/16 ,  C07D209/12

Abstract: The disclosure provides compounds of Formula I, deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, including use in treating APOL1 mediated kidney disease.

公开(公告)号：US20190322673A1

公开(公告)日：2019-10-24

申请号：US16391407

申请日：2019-04-23

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： David J. Lauffer ,  Guy Bemis ,  Michael Boyd ,  David Deininger ,  Hongbo Deng ,  Warren Dorsch ,  Wenxin Gu ,  Russell R. Hoover ,  Mac Arthur Johnson, JR. ,  Mark Willem Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Marina Penney ,  Darin Takemoto ,  Nathan D. Waal ,  Tiansheng Weng

IPC: C07D487/04 ,  C07D491/20 ,  C07D487/14 ,  C07D471/04 ,  C07D471/14 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

公开(公告)号：US09394302B2

公开(公告)日：2016-07-19

申请号：US14666567

申请日：2015-03-24

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  Michael J. Boyd ,  Ioana Davies ,  Hongbo Deng ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Joseph M. Kennedy ,  Brian Ledford ,  Mark W. Ledeboer ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang

IPC: C07D471/04 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6561

CPC classification number: C07D471/04 ,  A61K31/215 ,  A61K31/351 ,  A61K31/444 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6561

Abstract: This invention provides methods of preparing 3-(pyrimidin-2-yl)-1H-pyrrolo[2,3-b]pyridines and 3-(pyrimidin-2-yl)-1H-pyrazolo[3,4-b]pyridines, or pharmaceutically acceptable salts thereof that are useful for inhibiting the replication of influenza viruses in a biological sample or patient, reducing the amount of influenza viruses in a biological sample or patient, and treating influenza in a patient.

Abstract translation: 本发明提供3-（嘧啶-2-基）-1H-吡咯并[2,3-b]吡啶和3-（嘧啶-2-基）-1H-吡唑并[3,4-b]吡啶的制备方法， 或其药学上可接受的盐，其可用于抑制生物样品或患者中流感病毒的复制，减少生物样品或患者中的流感病毒的数量，以及治疗患者的流感。

公开(公告)号：US08871774B2

公开(公告)日：2014-10-28

申请号：US13918048

申请日：2013-06-14

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Ioana Davies ,  John P. Duffy ,  Huai Gao ,  Jun Feng ,  Jianglin Liang ,  Joseph M. Kennedy ,  Mark W. Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Emanuele Perola

IPC: A01N43/54 ,  C07D239/42 ,  C07D401/04 ,  A61K31/5377 ,  A61K31/506 ,  A61K45/06 ,  C07D471/04

CPC classification number: C07D471/04 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract translation: 抑制生物样品或患者中流感病毒复制，减少生物样品或患者中的流感病毒数量和治疗患者流感的方法包括向所述生物样本或患者施用有效量的 由结构式（I）表示的化合物或其药学上可接受的盐，其中结构式（I）的值如本文所述。 化合物由结构式（I）表示或其药学上可接受的盐，其中结构式（I）的值如本文所述。 药物组合物包含有效量的这种化合物或其药学上可接受的盐，以及药学上可接受的载体，佐剂或媒介物。

公开(公告)号：US20180078553A1

公开(公告)日：2018-03-22

申请号：US15718186

申请日：2017-09-28

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  John J. Court ,  Hongbo Deng ,  Ioana Davies ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Dylan H. Jacobs ,  Joseph M. Kennedy ,  Mark W. Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang ,  M. Woods Wannamaker ,  Randal Byrn ,  Yi Zhou ,  Chao Lin ,  Min Jiang ,  Steven Jones ,  Ursula A. Germann ,  Francesco G. Salituro ,  Ann Dak-Yee Kwong

IPC: A61K31/506

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D239/30 ,  C07D401/04 ,  C07D401/10 ,  C07D471/04

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

公开(公告)号：US08829007B2

公开(公告)日：2014-09-09

申请号：US14098867

申请日：2013-12-06

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  John J. Court ,  Hongbo Deng ,  Ioana Davies ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Dylan H. Jacobs ,  Joseph M. Kennedy ,  Mark W. Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang ,  M. Woods Wannamaker ,  Randal Bym ,  Yi Zhou ,  Chao Lin ,  Min Jiang ,  Steven Jones ,  Ursula A. Germann ,  Francesco G. Salituro ,  Ann Dak-Yee Kwong

IPC: C07D239/12 ,  C07D401/04 ,  C07D401/10 ,  C07D239/30

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/553 ,  C07D239/30 ,  C07D401/04 ,  C07D401/10 ,  C07D471/04

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

Abstract translation: 抑制生物样品或患者中流感病毒复制，减少生物样品或患者中的流感病毒数量和治疗患者流感的方法包括向所述生物样本或患者施用有效量的 由结构式（I）表示的化合物或其药学上可接受的盐，其中结构式（IA）的值如本文所述。 化合物由结构式（IA）或其药学上可接受的盐表示，其中结构式（IA）的值如本文所述。 药物组合物包含有效量的这种化合物或其药学上可接受的盐，以及药学上可接受的载体，佐剂或媒介物。

公开(公告)号：US20190151314A1

公开(公告)日：2019-05-23

申请号：US16016917

申请日：2018-06-25

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  John J. Court ,  Hongbo Deng ,  loana Davies ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Dylan H. Jacobs ,  Joseph M. Kennedy ,  Mark W. Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang ,  M. Woods Wannamaker ,  Randal Byrn ,  Yi Zhou ,  Chao Lin ,  Min Jiang ,  Steven Jones ,  Ursula A. Germann ,  Francesco G. Salituro ,  Ann Dak-Yee Kwong

IPC: A61K31/506 ,  A61K31/55 ,  C07D471/04 ,  A61K31/553 ,  A61K31/5377 ,  C07D401/10

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

公开(公告)号：US10039762B2

公开(公告)日：2018-08-07

申请号：US15718186

申请日：2017-09-28

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  John J. Court ,  Hongbo Deng ,  Ioana Davies ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Dylan H. Jacobs ,  Joseph M. Kennedy ,  Mark W. Ledeboer ,  Brian Ledford ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang ,  M. Woods Wannamaker ,  Randal Byrn ,  Yi Zhou ,  Chao Lin ,  Min Jiang ,  Steven Jones ,  Ursula A. Germann ,  Francesco G. Salituro ,  Ann Dak-Yee Kwong

IPC: C07D401/00 ,  A61K31/506 ,  C07D471/04

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

公开(公告)号：US20180155342A1

公开(公告)日：2018-06-07

申请号：US15872057

申请日：2018-01-16

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Paul S. Charifson ,  Michael P. Clark ,  Upul K. Bandarage ,  Randy S. Bethiel ,  Michael J. Boyd ,  loana Davies ,  Hongbo Deng ,  John P. Duffy ,  Luc J. Farmer ,  Huai Gao ,  Wenxin Gu ,  Joseph M. Kennedy ,  Brian Ledford ,  Mark W. Ledeboer ,  Francois Maltais ,  Emanuele Perola ,  Tiansheng Wang

IPC: C07D471/04 ,  C07F9/6561 ,  A61K45/06 ,  A61K31/506 ,  A61K31/215 ,  A61K31/444 ,  A61K31/351 ,  A61K31/497

CPC classification number: C07D471/04 ,  A61K31/215 ,  A61K31/351 ,  A61K31/444 ,  A61K31/497 ,  A61K31/506 ,  A61K45/06 ,  C07F9/6561

Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.